Agilent Technologies

Agilent Technologies is a global provider of analytical instruments, supplies, and software solutions serving pharmaceutical, biotech, clinical, and research laboratories worldwide. The company operates across multiple segments including chemical analysis and chromatography, life sciences research tools, clinical diagnostics and pathology, and pharmaceutical development services.

Agilent offers technologies for drug development, including mass spectrometry, liquid chromatography systems, cell analysis platforms, sequencing solutions, and laboratory informatics software. The company's portfolio spans hardware instruments, consumables, and software platforms designed to support regulated laboratory environments in pharmaceutical manufacturing, quality control, and research.

Founded as a spin-off from Hewlett-Packard on November 18, 1999, Agilent became a fully independent company on June 2, 2000, following HP's distribution of shares to shareholders. The separation represented the largest initial public offering in Silicon Valley history at the time, raising $2.1 billion. Agilent began operations with $8 billion in annual revenue and 43,000 employees.

Agilent acquired Biovectra, Avida Biomed, and e-MSion, expanding into biologics manufacturing and oligonucleotide therapeutics. The company maintains research partnerships through programs including the Agilent Research Catalyst awards and publishes ESG reporting.

Agilent Technologies serves pharmaceutical, biotechnology, and life sciences organizations as a core market segment, though the company is not pharma-exclusive. The life sciences division represents a significant portion of business operations alongside chemical analysis, diagnostics, and clinical pathology segments.

Pharmaceutical and biotech customers utilize Agilent's analytical instruments (mass spectrometry, liquid chromatography, cell analysis platforms, sequencing), consumables, and laboratory informatics software (SLIMS, OpenLab CDS) for drug development, quality control, manufacturing, and regulatory compliance applications. The company provides technologies supporting FDA 21 CFR Part 11, EU Annex 11, GAMP5, and GMP compliance requirements.

Named pharmaceutical customer Genentech (13,539 employees, $27 billion revenue) uses Agilent SLIMS for laboratory information management. Agilent acquired Biovectra, Avida Biomed, and e-MSion, adding biologics manufacturing, CDMO services, and oligonucleotide-therapeutics capabilities for biopharmaceutical customers.

Agilent offers pharma-specific product editions including SLIMS for Pharmaceutical Labs with dedicated stability studies modules, biopharma QC features, and integration with OpenLab CDS for chromatography data systems. Application notes and brochures target "Biopharma QC Digital Transformation" use cases. The company maintains research partnerships through Agilent Research Catalyst awards supporting pharmaceutical and academic research initiatives.

Customer count and pharma-customer percentage are undisclosed. The company serves large pharma, biotech, CDMOs, and medical device manufacturers across drug discovery, development, manufacturing, and quality control workflows.

$6.79 billion in trailing 12-month revenue as of July 31, 2025, up 4.48% year-over-year. Quarterly revenue was $1.74 billion in Q3 (ended July 31, 2025), up 10.14% quarter-over-quarter. Annual revenue for the fiscal year ended October 31, 2024 was $6.51 billion.

The company began operations in 1999 with $8 billion in annual revenue following the Hewlett-Packard spin-off. The November 1999 initial public offering raised $2.1 billion, representing the largest IPO in Silicon Valley history at that time.

Agilent acquired Biovectra, Avida Biomed, and e-MSion, expanding into biologics manufacturing, oligonucleotide therapeutics, CDMO capabilities, and analytical technology for biologics characterization.

Agilent is NASDAQ-listed (ticker: A) and publishes quarterly earnings releases and annual reports through investor relations. The company employs 17,900 people globally as of October 2024.

Agilent's product portfolio spans analytical instruments, consumables, and laboratory informatics software across three primary business segments: Life Sciences & Applied Markets, Diagnostics & Genomics, and Agilent CrossLab services.

**Analytical Instruments**: Mass spectrometry systems, liquid chromatography (HPLC, LC-MS), gas chromatography, atomic spectroscopy, cell analysis platforms, sequencing solutions, and microarrays for research, quality control, and regulatory testing applications.

**Laboratory Informatics Software**: SLIMS (Sample Lifecycle Information Management System) combining LIMS and ELN functionality; OpenLab CDS chromatography data system with FDA 21 CFR Part 11 compliance; analytical software suite integrating sample management, data acquisition, analysis, and workflow management. Version 7.2 of SLIMS introduces modernized interface, touchscreen protocol execution, and deeper instrument integration.

**Consumables & Supplies**: Columns, reagents, standards, sample preparation products, and replacement parts supporting analytical instrument operations and method development.

**Product Strategy**: Integrated suite approach connecting instruments with software (OpenLab CDS, SLIMS, Alissa Platform) and business systems (SAP, iLab). Emphasis on cloud-native deployment options, browser-based access, and mobile tablet compatibility. Pre-configured industry packages via SLIMS Store library accelerate deployment for pharmaceutical, biobanking, NGS, and analytical testing workflows.

**Innovation**: Recent releases emphasize digital transformation for biopharma QC, touchscreen-optimized protocols, automated data flow from instruments to eliminate manual transcription, and compliance-ready technical controls for FDA 21 CFR Part 11, EU Annex 11, and GAMP5 requirements. Strategic acquisitions (Biovectra, Avida Biomed, e-MSion) expand biologics characterization and oligonucleotide therapeutics capabilities.

Agilent integrates with business systems including SAP for enterprise resource planning, identity management platforms for secure authentication, and billing systems for laboratory operations. The company's SLIMS platform connects to Agilent analytical software including OpenLab CDS for chromatography data management, iLab for core facility management, and Alissa Platform for genomics interpretation.

Laboratory instrument integration spans sequencers, analyzers, chromatography systems, and lab balances with direct connections to eliminate manual data entry. Third-party integrations are available via APIs for custom workflow development and system connectivity.

Agilent maintains research partnerships through the Agilent Research Catalyst awards program, supporting pharmaceutical and academic research initiatives. The company participates in industry standards development.

Cloud-deployment partnerships are undisclosed. SLIMS supports hosting via Agilent-managed infrastructure, customer-preferred cloud providers (AWS, Azure, and GCP compatibility implied but not stated), or on-premise installations. Implementation and consulting partner networks are undisclosed.

Agilent provides professional services including implementation support, training, and validation assistance for regulated laboratory environments. SLIMS implementation is structured as paid Statements of Work with milestone-based billing, with professional services representing significant project costs that can double or triple initial software investment according to third-party reviews.

Implementation services emphasize "rapid and realistic" deployment transitioning to digital at the lab's pace, with time-to-value prioritization. Pre-configured industry packages from the SLIMS Store library accelerate deployment for pharmaceutical, biobanking, NGS, analytical testing, cannabis, and PFAS testing applications. Agilent consultants and certified partners provide custom configuration work for complex deployments.

Training services support user adoption for instrument operation, software workflows, and compliance requirements. Validation assistance helps pharmaceutical and biotech customers meet FDA 21 CFR Part 11, EU Annex 11, and GAMP5 regulatory expectations for computerized system validation.

Support availability — 24/7 coverage, regional support, languages — is undisclosed. Customer success programs, user communities, conferences, and certification programs are undisclosed.

Agilent's CrossLab services division provides consumables, supplies, and ongoing support for the installed instrument base. Service-level agreements and support tiers are undisclosed.

Agilent Technologies is a publicly-traded company on NASDAQ (ticker: A) with $6.79 billion in trailing 12-month revenue and 17,900 employees globally as of 2024. The company originated as a 1999 spin-off from Hewlett-Packard, inheriting HP's analytical instrumentation and life sciences businesses along with $8 billion in revenue at founding.

OpenLab CDS and SLIMS meet compliance requirements for FDA 21 CFR Part 11, EU Annex 11, GAMP5, ISO/IEC 17025, and EPA 40 CFR Part 160 through built-in technical controls. The company supports biopharma customers with application notes on "Biopharma QC Digital Transformation" and dedicated pharmaceutical product editions.

Agilent publishes ESG reporting. The company maintains research partnerships through Agilent Research Catalyst awards supporting scientific advancement in pharmaceutical and academic institutions.

Agilent acquired Biovectra (biologics CDMO), Avida Biomed (oligonucleotide therapeutics), and e-MSion (mass spectrometry), expanding capabilities for biopharmaceutical applications. Customers include Genentech and organizations across pharmaceutical, biotech, clinical diagnostics, and research laboratory segments.

ISO 9001, ISO 27001, SOC 2 compliance, and third-party security audits are undisclosed at the product level. There is no Gartner, Forrester, or other analyst recognition, and no industry award, on record. Leadership-team information and thought-leadership content — whitepapers, blog, webinars — are undisclosed.

Agilent has operated for 25+ years since its 1999 spin-off from Hewlett-Packard. The company's corporate website (agilent.com) has global localization for multiple countries and regions, product-specific landing pages (explore.agilent.com/AgilentSlims, explore.agilent.com/agilentslims-pharma), and an investor relations portal.

Content and resources include product brochures, application notes (e.g., "Biopharma QC Digital Transformation"), technical specifications, and compliance documentation for FDA 21 CFR Part 11. The company provides downloadable materials supporting purchase evaluation. Free-trial availability and demo details are undisclosed.

SLIMS is listed on G2 and Capterra. User reviews highlight deployment flexibility, equipment integration, and workflow convenience as strengths, while professional services costs and implementation complexity are noted concerns.

Agilent pairs analytical instruments with laboratory informatics platforms (SLIMS, OpenLab CDS) and business systems. The company's laboratory informatics products compete in the LIMS, ELN, chromatography-data-system, and laboratory-execution-system markets, serving pharmaceutical, biotech, and analytical-testing laboratories in regulated environments.